The primary objective of this clinical trial is to determine if treatment with an
anti-inflammatory drug (delayed-release prednisone) improves the health-related quality of
life (HRQOL) of veterans with Gulf War Illness (GWI). The primary outcome measure is a change
from baseline of HRQOL with respect to physical functioning and symptoms. Secondary outcomes
measures include changes from baseline levels of GWI-associated biomarkers of inflammation in
peripheral blood, GWI-associated symptoms (chronic pain, fatigue, and cognitive impairment),
and HRQOL with respect to mental functioning.